Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Isonicotinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonicotinic Acid SCHEMBL3705303 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273147 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL11323095 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25271513 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273296 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25261209 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25269382 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25270921 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL5858849 | 0.95 | CA2 (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273196 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240322260-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS CONTAINING THE SAME | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2024-09-26 | — | — | US | claimed |
| EP-4318701-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS COMPRISING SAME | Contemporary Amperex Technology Co., Limited (CN) | 2024-02-07 | — | — | EP | claimed |
| WO-2023102793-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS COMPRISING SAME | 宁德时代新能源科技股份有限公司 | 2023-06-15 | — | — | WO | claimed |
| US-20240322260-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS CONTAINING THE SAME | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4318701-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS COMPRISING SAME | Contemporary Amperex Technology Co., Limited (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117321818-A | Secondary battery and electricity utilization device comprising same | 宁德时代新能源科技股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023102793-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS COMPRISING SAME | 宁德时代新能源科技股份有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-115335378-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-3160962-B1 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-10005766-B2 | Method for producing fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170158682-A1 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-08 | — | — | US | disclosed |
| EP-3160962-A1 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198817-A1 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005766-B2 | Method for producing fused heterocyclic compound | KCNH2, KCNH3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NAPRT 3521/4885ALDH1A1 440/4885CA2 694/4885 |
| US-20170158682-A1 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND | KCNH2, KCNH3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NAPRT 3521/4885ALDH1A1 440/4885CA2 694/4885 |
| US-20240322260-A1 | SECONDARY BATTERY AND ELECTRICAL APPARATUS CONTAINING THE SAME | SOD1, SOD3, CAT | NAPRT 3967/4885ALDH1A1 926/4885CA2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.